Search results
Showing 1156 to 1170 of 2187 results for guidelines
Discontinued Reference number: GID-NG10167
Immunoscore for predicting risk of colon cancer relapse (MIB269)
NICE has developed a medtech innovation briefing on Immunoscore for predicting risk of colon cancer relapse .
YOURmeds for medication support in long-term conditions (MIB289)
NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .
Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)
Evidence-based recommendations on sofosbuvir–velpatasvir (Epclusa) for treating chronic hepatitis C in adults.
Discontinued Reference number: GID-NG10166
Discontinued Reference number: GID-NG10053
NICE has developed a medtech innovation briefing (MIB) on narrow band imaging for Barrett’s oesophagus .
Early value assessment (EVA) guidance on CaRi-Heart for predicting cardiac risk in suspected coronary artery disease.
Late-stage assessment (LSA) guidance on intermittent urethral catheters for chronic incomplete bladder emptying in adults.
Discontinued Reference number: GID-PHG59
NICE has developed a medtech innovation briefing (MIB) on Peptest for diagnosing gastro-oesophageal reflux
Evidence-based recommendations on individually magnetic resonance imaging-designed unicompartmental interpositional implant insertion for osteoarthritis of the knee. This involves inserting an individually designed implant at the knee between the thigh and shin bones to realign the knee and prevent bone-on-bone rubbing.
View recommendations for HTG203Show all sections
Sections for HTG203
VEST external stent for coronary artery bypass grafts (MIB115)
NICE has developed a medtech innovation briefing (MIB) on the VEST external stent for coronary artery bypass grafts .
CORTRAK 2 Enteral Access System for placing nasoenteral feeding tubes (MIB48)
NICE has developed a medtech innovation briefing (MIB) on the CORTRAK 2 Enteral Access System for placing nasoenteral feeding tubes .
Irreversible electroporation for treating prostate cancer (HTG688)
Evidence-based recommendations on irreversible electroporation for treating prostate cancer. This involves using electrical pulses to destroy the cancer cells.
View recommendations for HTG688Show all sections